Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.
Tobin JWD, Keane C, Gunawardana J, Mollee P, Birch S, Hoang T, Lee J, Li L, Huang L, Murigneux V, Fink JL, Matigian N, Vari F, Francis S, Kridel R, Weigert O, Haebe S, Jurinovic V, Klapper W, Steidl C, Sehn LH, Law SC, Wykes MN, Gandhi MK. Tobin JWD, et al. Among authors: jurinovic v. J Clin Oncol. 2019 Dec 1;37(34):3300-3309. doi: 10.1200/JCO.18.02365. Epub 2019 Aug 28. J Clin Oncol. 2019. PMID: 31461379 Free PMC article.
X-linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL.
Carlet M, Schmelz K, Vergalli J, Herold T, Senft D, Jurinovic V, Hoffmann T, Proba J, Weichert N, Junghanß C, Roth M, Eschenburg G, Barz M, Henze G, Eckert C, Eggert A, Zuber J, Hundsdoerfer P, Jeremias I. Carlet M, et al. Among authors: jurinovic v. EMBO Mol Med. 2023 Jan 11;15(1):e14557. doi: 10.15252/emmm.202114557. Epub 2022 Nov 23. EMBO Mol Med. 2023. PMID: 36416169 Free PMC article.
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, Pott C, Kopp N, Murakami M, Horn H, Leich E, Moccia AA, Mottok A, Sunkavalli A, Van Hummelen P, Ducar M, Ennishi D, Shulha HP, Hother C, Connors JM, Sehn LH, Dreyling M, Neuberg D, Möller P, Feller AC, Hansmann ML, Stein H, Rosenwald A, Ott G, Klapper W, Unterhalt M, Hiddemann W, Gascoyne RD, Weinstock DM, Weigert O. Pastore A, et al. Among authors: jurinovic v. Lancet Oncol. 2015 Sep;16(9):1111-1122. doi: 10.1016/S1470-2045(15)00169-2. Epub 2015 Aug 6. Lancet Oncol. 2015. PMID: 26256760
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.
Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, Rosenwald A, Ott G, Klapper W, Zelenetz AD, Barr PM, Friedberg JW, Ansell S, Sehn LH, Connors JM, Gascoyne RD, Hiddemann W, Unterhalt M, Weinstock DM, Weigert O. Jurinovic V, et al. Blood. 2016 Aug 25;128(8):1112-20. doi: 10.1182/blood-2016-05-717355. Epub 2016 Jul 14. Blood. 2016. PMID: 27418643 Free PMC article.
FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.
Mottok A, Jurinovic V, Farinha P, Rosenwald A, Leich E, Ott G, Horn H, Klapper W, Boesl M, Hiddemann W, Steidl C, Connors JM, Sehn LH, Gascoyne RD, Hoster E, Weigert O, Kridel R. Mottok A, et al. Among authors: jurinovic v. Blood. 2018 Jan 11;131(2):226-235. doi: 10.1182/blood-2017-08-799080. Epub 2017 Nov 9. Blood. 2018. PMID: 29122756 Free PMC article. Clinical Trial.
Impact of age on genetics and treatment efficacy in follicular lymphoma.
Alig S, Jurinovic V, Pastore A, Bararia D, Häbe S, Hellmuth JC, Kridel R, Gascoyne R, Schmidt C, Zöllner AK, Buske C, Dreyling M, Unterhalt M, Hiddemann W, Hoster E, Weigert O. Alig S, et al. Among authors: jurinovic v. Haematologica. 2018 Aug;103(8):e364-e367. doi: 10.3324/haematol.2018.187773. Epub 2018 Mar 15. Haematologica. 2018. PMID: 29545350 Free PMC article. No abstract available.
Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group.
Jurinovic V, Metzner B, Pfreundschuh M, Schmitz N, Wandt H, Keller U, Dreger P, Dreyling M, Hiddemann W, Unterhalt M, Hoster E, Weigert O. Jurinovic V, et al. Biol Blood Marrow Transplant. 2018 Jun;24(6):1172-1179. doi: 10.1016/j.bbmt.2018.03.022. Epub 2018 Mar 29. Biol Blood Marrow Transplant. 2018. PMID: 29605716 Free article. Clinical Trial.
Convergence of risk prediction models in follicular lymphoma.
Silva A, Bassim S, Sarkozy C, Mottok A, Lackraj T, Jurinovic V, Brodtkorb M, Lingjaerde OC, Sehn LH, Gascoyne RD, Weigert O, Steidl C, Kridel R. Silva A, et al. Among authors: jurinovic v. Haematologica. 2019 Jun;104(6):e252-e255. doi: 10.3324/haematol.2018.209031. Epub 2019 Jan 3. Haematologica. 2019. PMID: 30606786 Free PMC article. No abstract available.
Impact of age on clinical risk scores in follicular lymphoma.
Alig S, Jurinovic V, Pastore A, Haebe S, Schmidt C, Zoellner AK, Dreyling M, Unterhalt M, Hoster E, Hiddemann W, Weigert O. Alig S, et al. Among authors: jurinovic v. Blood Adv. 2019 Apr 9;3(7):1033-1038. doi: 10.1182/bloodadvances.2019032136. Blood Adv. 2019. PMID: 30940638 Free PMC article.
Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles.
Staiger AM, Hoster E, Jurinovic V, Winter S, Leich E, Kalla C, Möller P, Bernd HW, Feller AC, Koch K, Klapper W, Stein H, Hansmann ML, Hartmann S, Dreyling M, Weigert O, Hiddemann W, Herfarth K, Rosenwald A, Engelhard M, Ott G, Horn H. Staiger AM, et al. Among authors: jurinovic v. Blood. 2020 Jan 16;135(3):181-190. doi: 10.1182/blood.2019000560. Blood. 2020. PMID: 31697802 Free article. Clinical Trial.
56 results